Synthesis and characterization of ruthenium(II) hydrazone complexes as anticancer chemotherapeutic agents: <i>in vitro</i> DNA/BSA protein binding and cytotoxicity assay

Eswaran, Jayanthi; Anusuya, M.; Bhuvanesh, Nattamai; Khalil, Khaled; Dharmaraj, N.

doi:10.1080/00958972.2015.1077950

Cited by 25 publications

(7 citation statements)

References 44 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 4 shows the structure-activity on several tumor cell lines of different ruthenium complexes. [114][115][116][117][118][119][120][121][122][123][124][125][126][127].…”

Section: Rapta Compoundsmentioning

confidence: 99%

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

León

Cadavid-Vargas²,

Virgilio³

et al. 2017

CMC

120

View full text Add to dashboard Cite

Cancer is a group of diseases involving abnormal cell growth. The cells grow uncontrollably with the potential to invade and spread to other parts of the body. This disease is one of the principal death causes in the world, thus becoming a significant topic of scientific research. On the other hand, transition metals play a fundamental role in different living systems. In particular, Metallodrugs represent new and powerful tools for diverse therapeutic applications. To date, various metallodrugs display interesting biological activities for chemotherapy. In this field, cisplatin was the first inorganic compound with high relevance in cancer treatment. This compound was a leader agent in clinical use. Toxicity and resistance problems trigger the development of other platinum drugs with better clinical perspective and also raise the scientific interest for the putative antitumor properties of V, Ru and Cu compounds. Several scientific articles show that complexes of these metals are the new metal-based drugs used in the treatment of several cancers, such us, lung, colon, breast, bladder, etc. In this review we recapitulate current information and new advances on antitumor in vitro effects of several organic and inorganic compounds derived from copper, ruthenium and vanadium. These metal derived compounds targeting DNA or cell proteins involved in cell signaling pathways related to cancer. The mechanisms of cell death of these metallodrugs have also been comprehensibly reviewed. The knowledge of these mechanisms of death and the relationship between chemical structure and biological activity may be useful for the design of new metal-based drugs with promising pharmacologic applications as anticancer agents.

show abstract

“…Table 4 shows the structure-activity on several tumor cell lines of different ruthenium complexes. [114][115][116][117][118][119][120][121][122][123][124][125][126][127].…”

Section: Rapta Compoundsmentioning

confidence: 99%

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

León

Cadavid-Vargas²,

Virgilio³

et al. 2017

CMC

120

View full text Add to dashboard Cite

show abstract

“…Hydrazone compounds (-NH-N=C-) and their complexes have been widely studied due to their facile synthesis and potential biological activities [1][2][3][4][5]. During recent years, many hydrazone compounds and their complexes have displayed novel structures and extensive applications in luminescent probes, antibacterial and antitumor agents, fluorescence markers, optical materials, and anticonvulsant agent [6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

The Synthesis and Crystal Structure of Two New Hydrazone Compounds

Wang

Tai

2016

Crystals

View full text Add to dashboard Cite

show abstract

“…Hydrazones and their metal complexes show a vital role in frequent fields such as biomedical, wastewater remediation, [ 1 ] optoelectronic, [ 2 ] analytical, [ 3 ] photoresponse, [ 4 ] catalytic, [ 5 ] and cytotoxicity [ 6 ] studies. They used also as anticancer, [ 7 ] antihypertensive, [ 8 ] antitubercular, [ 9 ] antiproliferative, [ 10 ] antitumor, [ 11–13 ] antioxidant, [ 14 ] and chemotherapeutic agents. [ 15 ]…”

Section: Introductionmentioning

confidence: 99%

New solvatochromic complexes of 1,2‐bis[(5,6‐diphenyl‐1,2,4‐triazin3‐yl)hydrazinylidene‐methyl]benzene: Synthesis, spectroscopic, biological, docking, and theoretical studies

Samy

Taha

Omar

2021

Applied Organom Chemis

View full text Add to dashboard Cite

A new bistriazine hydrazone ligand (H2L; H2BDTB) is derived from 5,6‐diphenyl‐1,2,4‐triazine‐3‐ylhydrazine (DTH) with o‐phthalaldehyde in ratio (2:1). The Fe(III), Co(II), Ni(II), Cu(II), and Th(IV) complexes (1–5), as well as the Co(II) complex (6) (prepared in the presence of cetyltrimethylammonium bromide [CTAB]), are synthesized. They are characterized by elemental analyses, spectral (ultraviolet–visible [UV–Vis], infrared [IR], mass, 1H NMR, and electron spin resonance [ESR]), magnetic susceptibility, molar conductivity, and thermal gravimetric analysis (TGA) measurements; and morphological structures are scanned by electron microscopy (SEM) that showed rod shape, irregular bulk sheets, and fused aggregated clusters for free ligand, Co(II) complexes (2 and 6), respectively. Moreover, cobalt(II) complex (6) exhibited an octahedral geometry; however, cobalt(II) complex (2) showed square planar geometry as deduced from magnetic moment and UV–Vis measurements. Fluorescence spectra for ligand and its Fe(III) and Th(IV) complexes have been measured in different solvents to investigate their solvatochromic behavior that used to estimate dipole moments either in ground and excited states. The antimicrobial and antitumor activities of free ligand and its complexes were investigated, in addition to molecular docking studies using MOE 2014.0901 software (PDB. I.D.3ce3). The data showed that Co(II) complex (6) can be nominated as one of the most powerful antitumor. The theoretical calculation for bistriazine ligand and its complexes were performed using DFT and PM3, and the data are correlated with the experimental results.

show abstract

Synthesis and characterization of ruthenium(II) hydrazone complexes as anticancer chemotherapeutic agents: in vitro DNA/BSA protein binding and cytotoxicity assay

Cited by 25 publications

References 44 publications

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

The Synthesis and Crystal Structure of Two New Hydrazone Compounds

New solvatochromic complexes of 1,2‐bis[(5,6‐diphenyl‐1,2,4‐triazin3‐yl)hydrazinylidene‐methyl]benzene: Synthesis, spectroscopic, biological, docking, and theoretical studies

Contact Info

Product

Resources

About